Developmental stage biopharmaceutical company Silo Pharma Inc (Nasdaq:SILO) announced on Tuesday that it has entered into an exclusive global licence agreement to further develop, manufacture and commercialise its Alzheimer's drug SPC-14.
The company aims to expedite drug development using the FDA's streamlined 505(b)(2) pathway, potentially reducing costs and timelines.
Silo CEO Eric Weisblum believes SPC-14 could address a significant unmet medical need. Early pre-clinical data suggests potential benefits in stress reduction and cognitive improvement.
This announcement follows a similar licensing deal for Silo's lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval